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Foreword 
 
The evaluation of research and doctoral training is being carried out in the years 2010–2012 and will end in 
2012. The steering group appointed by the Rector in January 2010 set the conditions for participating in 
the evaluation and prepared the Terms of Reference to present the evaluation procedure and criteria. The 
publications and other scientific activities included in the evaluation covered the years 2005–2010. 
The participating unit in the evaluation was defined as a Researcher Community (RC). To obtain a 
critical mass with university-level impact, the number of members was set to range from 20 to 120. The 
RCs were required to contain researchers in all stages of their research career, from doctoral students to 
principal investigators (PIs). All in all, 136 Researcher Communities participated in this voluntary 
evaluation, 5857 persons in total, of whom 1131 were principal investigators. PIs were allowed to 
participate in two communities in certain cases, and 72 of them used this opportunity and participated in 
two RCs. 
This evaluation enabled researchers to define RCs from the “bottom up” and across disciplines. The aim 
of the evaluation was not to assess individual performance but a community with shared aims and 
researcher-training activities. The RCs were able to choose among five different categories that 
characterised the status and main aims of their research. The steering group considered the process of 
applying to participate in the evaluation to be important, which lead to the establishment of these 
categories. In addition, providing a service for the RCs to enable them to benchmark their research at the 
global level was a main goal of the evaluation. 
The data for the evaluation consisted of the RCs’ answers to evaluation questions on supplied e-forms 
and a compilation extracted from the TUHAT – Research Information System (RIS) on 12 April 2011. The 
compilation covered scientific and other publications as well as certain areas of scientific activities. During 
the process, the RCs were asked to check the list of publications and other scientific activities and make 
corrections if needed. These TUHAT compilations are public and available on the evaluation project sites 
of each RC in the TUHAT-RIS. 
In addition to the e-form and TUHAT compilation, University of Leiden (CWTS) carried out bibliometric 
analyses from the articles included in the Web of Science (WoS). This was done on University and RC 
levels. In cases where the publication forums of the RC were clearly not represented by the WoS data, the 
Library of the University of Helsinki conducted a separate analysis of the publications. This was done for 
66 RCs representing the humanities and social sciences. 
The evaluation office also carried out an enquiry targeted to the supervisors and PhD candidates about 
the organisation of doctoral studies at the University of Helsinki. This and other documents describing the 
University and the Finnish higher education system were provided to the panellists. 
The panel feedback for each RC is unique and presented as an entity. The first collective evaluation 
reports available for the whole panel were prepared in July–August 2011. The reports were accessible to all 
panel members via the electronic evaluation platform in August. Scoring from 1 to 5 was used to 
complement written feedback in association with evaluation questions 1–4 (scientific focus and quality, 
doctoral training, societal impact, cooperation) and in addition to the category evaluating the fitness for 
participation in the evaluation. Panellists used the international level as a point of comparison in the 
evaluation. Scoring was not expected to go along with a preset deviation. 
Each of the draft reports were discussed and dealt with by the panel in meetings in Helsinki (from 11 
September to 13 September or from 18 September to 20 September 2011). In these meetings the panels 
also examined the deviations among the scores and finalised the draft reports together. 
The current RC-specific report deals shortly with the background of the evaluation and the terms of 
participation. The main evaluation feedback is provided in the evaluation report, organised according to 
the evaluation questions. The original material provided by the RCs for the panellists has been attached to 
these documents. 
 
 
 
 
 
 
 
 
 
On behalf of the evaluation steering group and office, I sincerely wish to thank you warmly for your 
participation in this evaluation. The effort you made in submitting the data to TUHAT-RIS is gratefully 
acknowledged by the University. We wish that you find this panel feedback useful in many ways. The 
bibliometric profiles may open a new view on your publication forums and provide a perspective for 
discussion on your choice of forums. We especially hope that this evaluation report will help you in setting 
the future goals of your research. 
 
Johanna Björkroth 
Vice-Rector 
Chair of the Steering Group of the Evaluation 
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Panel members 
CHAIR 
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Karolinska Institute, Sweden 
 
VICE-CHAIR 
Professor Cornelia van Duijn 
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Erasmus Medical Centre, the Netherlands 
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Molecular cell biology, cell adhesion, cancer biology 
University of Turku, VTT Technical Research Centre, Finland 
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Immunology, medical microbiology 
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University of Münster, Germany 
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The panel, independently, evaluated all the submitted material and was responsible for the 
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discussion and report writing. 
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External Experts 
Professor Olli Carpén 
Pathology, cancer cell metastasis 
University of Turku 
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Dr Seppo Saari, Doc., Senior Adviser in Evaluation, was responsible for the entire 
evaluation, its planning and implementation and acted as an Editor-in-chief of the 
reports. 
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August 2010 to July 2011. 
MSocSc Paula Ranne, Planning Officer, was responsible for organising the panel 
meetings and all the other practical issues like agreements and fees and editing a 
part the RC-specific reports. She worked in the evaluation office from March 2011 
to January 2012. 
Mr Antti Moilanen, Project Secretary, was responsible for editing the reports. He 
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Mrs Aija Kaitera, Project Manager of TUHAT-RIS served the project ex officio 
providing the evaluation project with the updated information from TUHAT-RIS. 
The TUHAT office assisted in mapping the publications with CWTS/University of 
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MA Liisa Ekebom, Assisting Officer, served in TUHAT-RIS updating the 
publications for the evaluation. She also assisted the UH/Library analyses. 
BA Liisa Jäppinen, Assisting Officer, served in TUHAT-RIS updating the 
publications for the evaluation. 
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applicable. 
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Acronyms and abbreviations applied in the report 
 
External competitive funding 
AF – Academy of Finland 
TEKES - Finnish Funding Agency for Technology and Innovation  
EU - European Union 
ERC - European Research Council 
International and national foundations 
FP7/6 etc. /Framework Programmes/Funding of European Commission 
 
Evaluation marks 
Outstanding (5) 
Excellent  (4) 
Very Good  (3) 
Good  (2) 
Sufficient  (1) 
 
Abbreviations of Bibliometric Indicators 
P - Number of publications 
TCS – Total number of citations 
MCS - Number of citations per publication, excluding self-citations 
PNC - Percentage of uncited publications 
MNCS - Field-normalized number of citations per publication 
MNJS - Field-normalized average journal impact 
THCP10 - Field-normalized proportion highly cited publications (top 10%) 
INT_COV - Internal coverage, the average amount of references covered by the WoS 
WoS – Thomson Reuters Web of Science Databases 
 
Participation category 
Category 1. The research of the participating community represents the international cutting edge in its 
field. 
Category 2. The research of the participating community is of high quality, but the community in its 
present composition has yet to achieve strong international recognition or a clear break-through. 
Category 3. The research of the participating community is distinct from mainstream research, and the 
special features of the research tradition in the field must be considered in the evaluation. 
Category 4. The research of the participating community represents an innovative opening. 
Category 5. The research of the participating community has a highly significant societal impact. 
 
Research focus areas of the University of Helsinki 
Focus area 1: The basic structure, materials and natural resources of the physical world 
Focus area 2: The basic structure of life 
Focus area 3: The changing environment – clean water 
Focus area 4: The thinking and learning human being 
Focus area 5: Welfare and safety 
Focus area 6: Clinical research 
Focus area 7: Precise reasoning 
Focus area 8: Language and culture 
Focus area 9: Social justice 
Focus area 10: Globalisation and social change 
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1 Introduction to the Evaluation 
1.1 RC-specific evaluation reports 
The participants in the evaluation of research and doctoral training were Researcher Communities 
(hereafter referred to as the RC). The RC refers to the group of researchers who registered together in the 
evaluation of their research and doctoral training. Preconditions in forming RCs were stated in the 
Guidelines for the Participating Researcher Communities. The RCs defined themselves whether their 
compositions should be considered well-established or new. 
It is essential to emphasise that the evaluation combines both meta-evaluation1 and traditional 
research assessment exercise and its focus is both on the research outcomes and procedures associated 
with research and doctoral training. The approach to the evaluation is enhancement-led where self-
evaluation constituted the main information. The answers to the evaluation questions formed together 
with the information of publications and other scientific activities an entity that was to be reviewed as a 
whole. 
The present evaluation recognizes and justifies the diversity of research practices and publication 
traditions. Traditional Research Assessment Exercises do not necessarily value high quality research with 
low volumes or research distinct from mainstream research. It is challenging to expose the diversity of 
research to fair comparison. To understand the essence of different research practices and to do justice to 
their diversity was one of the main challenges of the present evaluation method. Understanding the 
divergent starting points of the RCs demanded sensitivity from the evaluators. 
1.2 Aims and objectives in the evaluation 
The aims of the evaluation are as follows: 
 to improve the level of research and doctoral training at the University of Helsinki and to raise 
their international profile in accordance with the University’s strategic policies. The improvement 
of doctoral training should be compared to the University’s policy.2 
 to enhance the research conducted at the University by taking into account the diversity, 
originality, multidisciplinary nature, success and field-specificity, 
 to recognize the conditions and prerequisites under which excellent, original and high-impact 
research is carried out, 
 to offer the academic community the opportunity to receive topical and versatile international 
peer feedback, 
 to better recognize the University’s research potential. 
 to exploit the University’s TUHAT research information system to enable transparency of 
publishing activities and in the production of reliable, comparable data. 
1.3 Evaluation method 
The evaluation can be considered as an enhancement-led evaluation. Instead of ranking, the main aim is to 
provide useful information for the enhancement of research and doctoral training of the participating RCs. 
The comparison should take into account each field of science and acknowledge their special character. 
                                                                
1 The panellists did not read research reports or abstracts but instead, they evaluated answers to the evaluation 
questions, tables and compilations of publications, other scientific activities, bibliometrics or comparable analyses. 
2
 Policies on doctoral degrees and other postgraduate degrees at the University of Helsinki.  
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The comparison produced information about the present status and factors that have lead to success. Also 
challenges in the operations and outcomes were recognized. 
The evaluation approach has been designed to recognize better the significance and specific nature of 
researcher communities and research areas in the multidisciplinary top-level university. Furthermore, one 
of the aims of the evaluation is to bring to light those evaluation aspects that differ from the prevalent 
ones. Thus the views of various fields of research can be described and research arising from various 
starting points understood better. The doctoral training is integrated into the evaluation as a natural 
component related to research. Operational processes of doctoral training are being examined in the 
evaluation. 
 
Five stages of the evaluation method were: 
1. Registration – Stage 1 
2. Self-evaluation – Stage 2 
3. TUHAT3 compilations on publications and other scientific activities4 
4. External evaluation 
5. Public reporting 
1.4 Implementation of the external evaluation 
Five Evaluation Panels 
Five evaluation panels consisted of independent, renowned and highly respected experts. The main 
domains of the panels are: 
1. biological, agricultural and veterinary sciences 
2. medicine, biomedicine and health sciences 
3. natural sciences 
4. humanities 
5. social sciences 
The University invited 10 renowned scientists to act as chairs or vice-chairs of the five panels based on 
the suggestions of faculties and independent institutes. Besides leading the work of the panel, an 
additional role of the chairs was to discuss with other panel chairs in order to adopt a broadly similar 
approach. The panel chairs and vice-chairs had a pre-meeting on 27 May 2011 in Amsterdam. 
The panel compositions were nominated by the Rector of the University 27 April 2011. The participating 
RCs suggested the panel members. The total number of panel members was 50. The reason for a smaller 
number of panellists as compared to the previous evaluations was the character of the evaluation as a 
meta-evaluation. The panellists did not read research reports or abstracts but instead, they evaluated 
answers to the evaluation questions, tables and compilations of publications, other scientific activities, 
bibliometrics and comparable analyses. 
 
The panel meetings were held in Helsinki: 
 On 11–13 September 2011: (1) biological, agricultural and veterinary sciences, (2) medicine, 
biomedicine and health sciences and (3) natural sciences.  
 On 18–20 September 2011: (4) humanities and (5) social sciences. 
  
                                                                
3 TUHAT (acronym) of Research Information System (RIS) of the University of Helsinki 
4 Supervision of thesis, prizes and awards, editorial work and peer reviews, participation in committees, boards and 
networks and public appearances. 
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1.5 Evaluation material 
The main material in the evaluation was the RCs’ self-evaluations that were qualitative in character and 
allowed the RCs to choose what was important to mention or emphasise and what was left unmentioned. 
The present evaluation is exceptional at least in the Finnish context because it is based on both the 
evaluation documentation (self-evaluation questions, publications and other scientific activities) and the 
bibliometric reports. All documents were delivered to the panellists for examination. 
Traditional bibliometrics can be reasonably done mainly in medicine, biosciences and natural sciences 
when using the Web of Science database, for example. Bibliometrics, provided by CWTS/The Centre for 
Science and Technology Studies, University of Leiden, cover only the publications that include WoS 
identification in the TUHAT-RIS. 
Traditional bibliometrics are seldom relevant in humanities and social sciences because the 
international comparable databases do not store every type of high quality research publications, such as 
books and monographs and scientific journals in other languages than English. The Helsinki University 
Library has done analysis to the RCs, if their publications were not well represented in the Web of Science 
databases (RCs should have at least 50 publications and internal coverage of publications more than 40%) 
– it meant 58 RCs. The bibliometric material for the evaluation panels was available in June 2011. The RC-
specific bibliometric reports are attached at the end of each report. 
The panels were provided with the evaluation material and all other necessary background information, 
such as the basic information about the University of Helsinki and the Finnish higher education system. 
 
Evaluation material 
1. Registration documents of the RCs for the background information 
2. Self evaluation material – answers to the evaluation questions 
3. Publications and other scientific activities based on the TUHAT RIS: 
3.1. statistics of publications 
3.2. list of publications 
3.3. statistics of other scientific activities 
3.4. list of other scientific activities 
4. Bibliometrics and comparable analyses: 
4.1. Analyses of publications based on the verification of TUHAT-RIS publications with the Web 
of Science publications (CWTS/University of Leiden) 
4.2. Publication statistics analysed by the Helsinki University Library - mainly for humanities and 
social sciences 
5. University level survey on doctoral training (August 2011) 
6. University level analysis on publications 2005–2010 (August 2011) provided by CWTS/University 
of Leiden 
 
Background material 
 
University of Helsinki 
- Basic information about the University of the Helsinki 
- The structure of doctoral training at the University of Helsinki 
- Previous evaluations of research at the University of Helsinki – links to the reports: 1998 and 2005 
 
The Finnish Universities/Research Institutes 
- Finnish University system 
- Evaluation of the Finnish National Innovation System 
- The State and Quality of Scientific Research in Finland. Publication of the Academy of Finland 
9/09. 
 
The evaluation panels were provided also with other relevant material on request before the meetings in 
Helsinki. 
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1.6 Evaluation questions and material 
The participating RCs answered the following evaluation questions which are presented according to the 
evaluation form. In addition, TUHAT RIS was used to provide the additional material as explained. For 
giving the feedback to the RCs, the panellists received the evaluation feedback form constructed in line 
with the evaluation questions: 
 
1. Focus and quality of the RC’s research 
 Description of 
- the RC’s research focus. 
- the quality of the RC’s research (incl. key research questions and results) 
- the scientific significance of the RC’s research in the research field(s) 
 Identification of the ways to strengthen the focus and improve the quality of the RC’s research 
The additional material: TUHAT compilation of the RC’s publications, analysis of the RC’s publications data 
(provided by University of Leiden and the Helsinki University Library) 
A written feedback from the aspects of: scientific quality, scientific significance, societal impact, 
innovativeness 
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
Numeric evaluation: OUTSTANDING (5), EXCELLENT (4), VERY GOOD (3), GOOD (2), SUFFICIENT (1) 
 
2. Practises and quality of doctoral training 
 Organising of the doctoral training in the RC. Description of the RC’s principles for: 
- recruitment and selection of doctoral candidates 
- supervision of doctoral candidates 
- collaboration with faculties, departments/institutes, and potential graduate schools/doctoral 
programmes 
- good practises and quality assurance in doctoral training 
- assuring of good career perspectives for the doctoral candidates/fresh doctorates 
 Identification of the RC’s strengths and challenges related to the practises and quality of doctoral 
training, and the actions planned for their development. 
The additional material: TUHAT compilation of the RC’s other scientific activities/supervision of doctoral 
dissertations 
A written feedback from the aspects of: processes and good practices related to leadership and 
management 
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
Numeric evaluation: OUTSTANDING (5), EXCELLENT (4), VERY GOOD (3), GOOD (2), SUFFICIENT (1) 
 
3. The societal impact of research and doctoral training 
 Description on how the RC interacts with and contributes to the society (collaboration with 
public, private and/or 3rd sector). 
 Identification of the ways to strengthen the societal impact of the RC’s research and doctoral 
training. 
The additional material: TUHAT compilation of the RC’s other scientific activities. 
A written feedback from the aspects of: societal impact, national and international collaboration, 
innovativeness 
 
  Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
Numeric evaluation: OUTSTANDING (5), EXCELLENT (4), VERY GOOD (3), GOOD (2), SUFFICIENT (1) 
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4. International and national (incl. intersectoral) research collaboration and researcher mobility 
 Description of  
- the RC’s research collaborations and joint doctoral training activities 
- how the RC has promoted researcher mobility 
 Identification of the RC’s strengths and challenges related to research collaboration and 
researcher mobility, and the actions planned for their development. 
A written feedback from the aspects of: scientific quality, national and international collaboration 
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
Numeric evaluation: OUTSTANDING (5), EXCELLENT (4), VERY GOOD (3), GOOD (2), SUFFICIENT (1) 
 
5. Operational conditions  
 Description of the operational conditions in the RC’s research environment (e.g. research 
infrastructure, balance between research and teaching duties). 
 Identification of the RC’s strengths and challenges related to operational conditions, and the 
actions planned for their development. 
A written feedback from the aspects of: processes and good practices related to leadership and 
management 
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
6. Leadership and management in the researcher community 
 Description of 
- the execution and processes of leadership in the RC 
- how the management-related responsibilities and roles are distributed in the RC 
- how the leadership- and management-related processes support 
- high quality research 
- collaboration between principal investigators and other researchers in the RC 
the RC’s research focus 
- strengthening of the RC’s know-how 
 Identification of the RC’s strengths and challenges related to leadership and management, and 
the actions planned for developing the processes 
 
7. External competitive funding of the RC 
 The RCs were asked to provide information of such external competitive funding, where: 
- the funding decisions have been made during 1.1.2005-31.12.2010, and 
- the administrator of the funding is/has been the University of Helsinki 
 On the e-form the RCs were asked to provide: 
1) The relevant funding source(s) from a given list (Academy of Finland/Research Council, TEKES/The 
Finnish Funding Agency for Technology and Innovation , EU, ERC, foundations, other national funding 
organisations, other international funding organisations), and 
2)The total sum of funding which the organisation in question had decided to allocate to the RCs 
members during 1.1.2005–31.12.2010. 
 
Competitive funding reported in the text is also to be considered when evaluating this point. 
A written feedback from the aspects of: scientific quality, scientific significance, societal impact, 
innovativeness, future significance 
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
8. The RC’s strategic action plan for 2011–2013 
 RC’s description of their future perspectives in relation to research and doctoral training. 
A written feedback from the aspects of: scientific quality, scientific significance, societal Impact, processes 
and good practices related to leadership and management, national and international collaboration, 
innovativeness, future significance 
 Strengths 
 Areas of development 
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 Other remarks 
 Recommendations 
 
9. Evaluation of the category of the RC in the context of entity of the evaluation material (1-8) 
 
The RC’s fitness to the chosen participation category 
A written feedback evaluating the RC’s fitness to the chosen participation category  
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
Numeric evaluation: OUTSTANDING (5), EXCELLENT (4), VERY GOOD (3), GOOD (2), SUFFICIENT (1) 
 
10. Short description of how the RC members contributed the compilation of the stage 2 material 
Comments on the compilation of evaluation material 
 
11. How the UH’s focus areas are presented in the RC’s research? 
Comments if applicable 
 
12. RC-specific main recommendations based on the previous questions 1–11 
 
13. RC-specific conclusions 
1.7 Evaluation criteria 
The panellists were expected to give evaluative and analytical feedback to each evaluation question 
according to their aspects in order to describe and justify the quality of the submitted material. In 
addition, the evaluation feedback was asked to be pointed out the level of the performance according to 
the following classifications: 
 outstanding  (5) 
 excellent  (4) 
 very good  (3) 
 good   (2) 
 sufficient  (1) 
 
Evaluation according to the criteria was to be made with thorough consideration of the entire 
evaluation material of the RC in question. Finally, in questions 1-4 and 9, the panellists were expected to 
classify their written feedback into one of the provided levels (the levels included respective descriptions, 
‘criteria’). Some panels used decimals in marks. The descriptive level was interpreted according to the 
integers and not rounding up the decimals by the editors. 
 
Description of criteria levels 
Question 1 – FOCUS AND QUALITY OF THE RC’S RESEARCH 
 
Classification: Criteria (level of procedures and results) 
Outstanding quality of procedures and results (5) 
Outstandingly strong research, also from international perspective. Attracts great international 
interest with a wide impact, including publications in leading journals and/or monographs published 
by leading international publishing houses. The research has world leading qualities. The research 
focus, key research questions scientific significance, societal impact and innovativeness are of 
outstanding quality. 
In cases where the research is of a national character and, in the judgement of the evaluators, should 
remain so, the concepts of ”international attention” or ”international impact” etc. in the grading 
criteria above may be replaced by ”international comparability”. 
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Operations and procedures are of outstanding quality, transparent and shared in the community. The 
improvement of research and other efforts are documented and operations and practices are in 
alignment with the documentation. The ambition to develop the community together is of 
outstanding quality. 
Excellent quality of procedures and results (4) 
Research of excellent quality. Typically published with great impact, also internationally. Without 
doubt, the research has a leading position in its field in Finland. 
Operations and procedures are of excellent quality, transparent and shared in the community. The 
improvement of research and other efforts are documented and operations and practices are to 
large extent in alignment with the documentation. The ambition to develop the community together 
is of excellent quality. 
Very good quality of procedures and results (3) 
The research is of such very good quality that it attracts wide national and international attention. 
Operations and procedures are of very good quality, transparent and shared in the community. The 
improvement of research and other efforts are documented and operations and practices are to 
large extent in alignment with the documentation. The ambition to develop the community together 
is of very good quality. 
Good quality of procedures and results (2) 
Good research attracting mainly national attention but possessing international potential, 
extraordinarily high relevance may motivate good research. 
Operations and procedures are of good quality, shared occasionally in the community. The 
improvement of research and other efforts are occasionally documented and operations and 
practices are to large extent in alignment with the documentation. The ambition to develop the 
community together is of good quality. 
Sufficient quality of procedures and results (1) 
In some cases the research is insufficient and reports do not gain wide circulation or do not have 
national or international attention. Research activities should be revised. 
Operations and procedures are of sufficient quality, shared occasionally in the community. The 
improvement of research and other efforts are occasionally documented and operations and 
practices are to some extent in alignment with the documentation. The ambition to develop the 
community together is of sufficient quality. 
 
Question 2 – DOCTORAL TRAINING 
Question 3 – SOCIETAL IMPACT 
Question 4 – COLLABORATION 
 
Classification: Criteria (level of procedures and results) 
Outstanding quality of procedures and results (5) 
Procedures are of outstanding quality, transparent and shared in the community. The practices and 
quality of doctoral training/societal impact/international and national collaboration/leadership and 
management are documented and operations and practices are in alignment with the 
documentation. The ambition to develop the community together is of outstanding quality. The 
procedures and results are regularly evaluated and the feedback has an effect on the planning. 
Excellent quality of procedures and results (4) 
Procedures are of excellent quality, transparent and shared in the community. The practices and 
quality of doctoral training/societal impact/international and national collaboration/leadership and 
management are documented and operations and practices are to large extent in alignment with the 
documentation. The ambition to develop the community together is of excellent quality. The 
procedures and outcomes are evaluated and the feedback has an effect on the planning. 
Very good quality of procedures and results (3) 
Procedures are of very good quality, transparent and shared in the community. The practices and 
quality of doctoral training/societal impact/international and national collaboration/leadership and 
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management are documented and operations and practices are to large extent in alignment with the 
documentation. The ambition to develop the community together is of very good quality. 
Good quality of procedures and results (2) 
Procedures are of good quality, shared occasionally in the community. The practices and quality of 
doctoral training/societal impact/international and national collaboration/leadership and 
management are documented and operations and practices are to large extent in alignment with the 
documentation. The ambition to develop the community together is of good quality. 
Sufficient quality of procedures and results (1) 
Procedures are of sufficient quality, transparent and shared in the community. The practices and 
quality of doctoral training/societal impact/international and national collaboration/leadership and 
management are occasionally documented and operations and practices are to some extent in 
alignment with the documentation. The ambition to develop the community together is of sufficient 
quality. 
 
Question 9 – CATEGORY 
Participation category – fitness for the category chosen 
The choice and justification for the chosen category below should be reflected in the RC’s responses to the 
evaluation questions 1–8. 
1. The research of the participating community represents the international cutting edge in its field. 
2. The research of the participating community is of high quality, but the community in its present 
composition has yet to achieve strong international recognition or a clear break-through. 
3. The research of the participating community is distinct from mainstream research, and the special 
features of the research tradition in the field must be considered in the evaluation. The research is 
of high quality and has great significance and impact in its field. However, the generally used 
research evaluation methods do not necessarily shed sufficient light on the merits of the 
research.  
4. The research of the participating community represents an innovative opening. A new opening can 
be an innovative combination of research fields, or it can be proven to have a special social, 
national or international demand or other significance. Even if the researcher community in its 
present composition has yet to obtain proof of international success, its members can produce 
convincing evidence of the high level of their previous research. 
5. The research of the participating community has a highly significant societal impact. The 
participating researcher community is able to justify the high social significance of its research. 
The research may relate to national legislation, media visibility or participation in social debate, 
or other activities promoting social development and human welfare. In addition to having 
societal impact, the research must be of a high standard. 
 
An example of outstanding fitness for category choice (5) 5 
The RC’s representation and argumentation for the chosen category were convincing. The RC recognized 
its real capacity and apparent outcomes in a wider context to the research communities. The specific 
character of the RC was well-recognized and well stated in the responses. The RC fitted optimally for the 
category. 
 
 Outstanding  (5) 
 Excellent  (4) 
 Very good  (3) 
 Good   (2) 
 Sufficient  (1) 
The above-mentioned definition of outstanding was only an example in order to assist the panellists in 
the positioning of the classification. There was no exact definition for the category fitness. 
                                                                
5 The panels discussed the category fitness and made the final conclusions of the interpretation of it. 
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1.8 Timetable of the evaluation 
The main timetable of the evaluation: 
1. Registration   November 2010 
2. Submission of self-evaluation materials  January–February 2011 
3. External peer review    May–September 2011 
4. Published reports    March–April 2012 
- University level public report 
- RC specific reports 
 
The entire evaluation was implemented during the university’s strategy period 2010–2012. The preliminary 
results were available for the planning of the following strategy period in late autumn 2011. The evaluation 
reports will be published in March/April 2012. More detailed time schedule is published in the University 
report. 
1.9 Evaluation feedback – consensus of the entire panel 
The panellists evaluated all the RC-specific material before the meetings in Helsinki and mailed the 
draft reports to the evaluation office. The latest interim versions were on-line available to all the panellists 
on the Wiki-sites. In September 2011, in Helsinki the panels discussed the material, revised the first draft 
reports and decided the final numeric evaluation. After the meetings in Helsinki, the panels continued 
working and finalised the reports before the end of November 2011. The final RC-specific reports are the 
consensus of the entire panel. 
The evaluation reports were written by the panels independently. During the editing process, the 
evaluation office requested some clarifications from the panels when necessary. The tone and style in the 
reports were not harmonized in the editing process. All the reports follow the original texts written by the 
panels as far as it was possible. 
The original evaluation material of the RCs, provided for the panellists is attached at the end of the 
report. It is essential to notice that the exported lists of publications and other scientific activities depend 
how the data was stored in the TUHAT-RIS by the RCs. 
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2 Evaluation feedback 
2.1 Focus and quality of the RC’s research 
 Description of 
 the RC’s research focus 
 the quality of the RC’s research (incl. key research questions and results) 
 the scientific significance of the RC’s research in the research field(s) 
 Identification of the ways to strengthen the focus and improve the quality of the RC’s research 
ASPECTS: Scientific quality, scientific significance, societal impact, innovativeness 
 
The RC is very heterogeneous covering areas around immunology from MHC genetics, transplantation 
immunology, allergy and cancer treatment with modified adenoviruses. The achievements are not very 
impressive only the ERC funding for professor Hemminki shows scientific excellence. Professor Renkonen’s 
achievements are also significant but he is already present also in the InfBio RC. 
The RC is too small to survive and it should be fused to the RC led by Professor Meri (InfBio RC), where 
e.g. whole virology studied in Meilahti Campus is well represented. 
Prof. Hemminki could also consider joining the CANBIO RC which is an outstanding RC led Prof. Kari 
Alitalo. 
Numeric evaluation: 2 (Good) 
2.2 Practises and quality of doctoral training 
 Organising of the doctoral training in the RC. Description of the RC’s principles for: 
 recruitment and selection of doctoral candidates 
 supervision of doctoral candidates 
 collaboration with faculties, departments/institutes, and potential graduate schools/doctoral 
programmes 
 good practises and quality assurance in doctoral training 
 assuring of good career perspectives for the doctoral candidates/fresh doctorates 
 Identification of the RC’s strengths and challenges related to the practises and quality of doctoral 
training, and the actions planned for their development. 
 Additional material: TUHAT compilation of the RC’s other scientific activities/supervision of doctoral 
dissertations 
ASPECTS: Processes and good practices related to leadership and management 
 
The RC has produced 16 PhDs during 2005–2010 with a good selection and recruitment of doctoral 
candidates. 
The RC has not been very active in developing the doctoral programme system in Meilahti campus 
area. 
 
Recommendation 
The RC should be more active in recruiting excellent PhD students and be more active in local doctoral 
programmes funded by the Ministry of Culture and Education and the Academy of Finland. 
Numeric evaluation: 3 (Very good) 
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2.3 The societal impact of research and doctoral training 
 Description on how the RC interacts with and contributes to the society (collaboration with public, 
private and/or 3rd sector). 
 Identification of the ways to strengthen the societal impact of the RC’s research and doctoral training. 
 Additional material: TUHAT compilation of the RC’s other scientific activities. 
ASPECTS: Societal impact, national and international collaboration, innovativeness 
 
In some areas the RC is interacting well with the society, but the RC is too small to have enough 
significance and impact in research or doctoral training. 
 
Recommendation 
Fuse the RC like described before. 
Numeric evaluation: 3 (Very good) 
2.4 International and national (incl. intersectoral) research 
collaboration and researcher mobility 
 Description of  
 the RC’s research collaborations and joint doctoral training activities 
 how the RC has promoted researcher mobility 
 Identification of the RC’s strengths and challenges related to research collaboration and researcher 
mobility, and the actions planned for their development. 
ASPECTS: Scientific quality, national and international collaboration 
 
The RC has national collaboration with clinical departments and the National Institute for Health and 
Welfare but the data contains only international collaboration of Docent Lokki which is not very 
impressive but the continuation of the research collaboration with Freiburg and Toronto is important. 
Numeric evaluation: 2 (Good) 
2.5 Operational conditions 
 Description of the operational conditions in the RC’s research environment (e.g. research 
infrastructure, balance between research and teaching duties). 
 Identification of the RC’s strengths and challenges related to operational conditions, and the actions 
planned for their development. 
ASPECTS: Processes and good practices related to leadership and management 
 
From the description of Docent Lokki, it seems that the research infrastructure is well maintained, but 
some difficulties are faced like Prof. Renkonen is currently the Dean of Medical Faculty with limited time 
resources but other group leaders are almost full-time researchers. Operational conditions might be 
improved if this RC is fused with the InfBio RC. 
2.6 Leadership and management in the researcher community 
 Description of  
 the execution and processes of leadership in the RC 
 how the management-related responsibilities and roles are distributed in the RC 
 how the leadership- and management-related processes support 
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 high quality research 
 collaboration between principal investigators and other researchers in the RC 
 the RC’s research focus 
 strengthening of the RC’s know-how 
 Identification of the RC’s strengths and challenges related to leadership and management, and the 
actions planned for developing the processes 
ASPECTS: Processes and good practices related to leadership and management 
 
This RC has four principal investigators, but the panel recommends that it would be better led by e.g. Prof. 
Akseli Hemminki with highest scientific excellence or fused with the InfBio RC. The current situation is not 
optimal because the groups are more or less selected randomly and do not seem to have clear, common 
goals. 
2.7 External competitive funding of the RC 
• The RCs were asked to provide information of such external competitive funding, where: 
• the funding decisions have been made during 1.1.2005–31.12.2010, and  
• the administrator of the funding is/has been the University of Helsinki 
• On the e-form the RCs were asked to provide: 
1) The relevant funding source(s) from a given list (Academy of Finland/Research Council, 
TEKES/The Finnish Funding Agency for Technology and Innovation, EU, ERC, foundations, other 
national funding organisations, other international funding organizations), and 
2) The total sum of funding which the organisation in question had decided to allocate to the RCs 
members during 1.1.2005–31.12.2010. 
Competitive funding reported in the text is also to be considered when evaluating this point. 
ASPECTS: Scientific quality, scientific significance, societal impact, innovativeness and future significance 
 
The competitive external funding is excellent highlighted with ERC funding to Prof. Hemminki and almost 
all the group leaders have significant funding from the Academy of Finland and other funding is also 
impressive including EVO, Juselius etc. funding. 
2.8 The RC’s strategic action plan for 2011–2013 
• RC’s description of their future perspectives in relation to research and doctoral training. 
ASPECTS: Scientific quality, scientific significance, societal Impact, processes and good practices related to 
leadership and management, national and international collaboration, innovativeness, future significance 
 
The funding for the RC is excellent also in the future, but better result in research would be obtained in a 
larger RC like InfBio. 
The panel would recommend fusion of these two RCs to obtain more strategic value of this important 
area of infection and immunity for the Helsinki University and Meilahti campus. 
2.9 Evaluation of the category of the RC in the context of entity of 
the evaluation material (1-8) 
The RC’s fitness to the chosen participation category. 
Category 2. The research of the participating community is of high quality, but the community in its present 
composition has yet to achieve strong international recognition or a clear break-through. 
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The RC without the InfBio RC does not fit to the chosen participation category. 
Numeric evaluation: 2 (Good) 
2.10 Short description of how the RC members contributed the 
compilation of the stage 2 material 
It looks like that Docent Lokki has herself compiled the material and other principal investigators have 
provided some information, but the material might lack some important aspects from other participants 
like national and international collaboration etc. 
2.11 How the UH’s focus areas are presented in the RC’s research 
Focus area 6: Clinical research 
 
No comment at this stage but the fusion with the InfBio RC maybe in the future be covered as an 
important research area of UH. 
2.12 RC-specific main recommendations 
The RC as such does not have a clear focus and this RC should be fused to the InfBio RC in order to  create 
a real Research Programme covering immunology, virology, bacteriology and infection and 
transplantation and this fusion would allow a great chance for translational medicine. 
2.13 RC-specific conclusions 
The RC in the current form is too small and diverse and does not seem to have a common goal. The RC 
with four principal investigators has excellent funding, but they would be more suitable in the InfBio RC. 
The fusion of these two RCs would be more impressive and significant RC. 
2.14 Preliminary findings in the University-level evaluation 
This RC led by Docent Lokki should be fused with the InfBio RC in order to create a critical mass of 
impressive research in their research areas. 
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3 Appendices 
A. Original evaluation material 
a. Registration material – Stage 1 
b. Answers to evaluation questions – Stage 2 
c. List of publications 
d. List of other scientific activities 
B. Bibliometric analyses 
a. Analysis provided by CWTS/University of Leiden 
b. Analysis provided by Helsinki University Library (66 RCs) 
 
 
 
 
 
International evaluation of research and doctoral training 
at the University of Helsinki 2005-2010 
 
         RC-SPECIFIC MATERIAL FOR THE PEER REVIEW 
 
 
 
 
NAME OF THE RESEARCHER COMMUNITY:  
Inflammatory Diseases-towards Translational Medicine (ID-TM) 
 
LEADER OF THE RESEARCHER COMMUNITY:  
Research Director Marja-Liisa Lokki, Transplantation Laboratory, Haartman Institute, Faculty of 
Medicine 
 
 
RC-SPECIFIC MATERIAL FOR THE PEER REVIEW: 
 Material submitted by the RC at stages 1 and 2 of the evaluation 
- STAGE 1 material: RC’s registration form (incl. list of RC participants in an excel table) 
- STAGE 2 material: RC’s answers to evaluation questions 
 TUHAT compilations of the RC members’ publications 1.1.2005-31.12.2010 
 TUHAT compilations of the RC members’ other scientific activities 1.1.2005-31.12.2010 
 Web of Science(WoS)-based bibliometrics of the RC’s publications data 1.1.2005-31.12.2010 
(analysis carried out by CWTS, Leiden University) 
NB! Since Web of Science(WoS)-based bibliometrics does not provide representative results for most RCs representing 
humanities, social sciences and computer sciences, the publications of these RCs will be analyzed by the UH Library 
(results available by the end of June, 2011) 
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INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE 
UNIVERSITY OF HELSINKI  
 
RC-SPECIFIC STAGE 1 MATERIAL (registration form) 
 
 
 
 
Name: Lokki, Marja-Liisa 
E-mail:  
Phone: +358 9 191 26614 
Affiliation: Haartman Institute, University of Helsinki 
Street address: Haartmaninkatu 3, 00290 Helsinki 
 
 
Name of the participating RC (max. 30 characters): Inflammatory Diseases-towards Translational Medicine 
Acronym for the participating RC (max. 10 characters): ID-TM 
Description of the operational basis in 2005-2010 (eg. research collaboration, joint doctoral training 
activities) on which the RC was formed (MAX. 2200 characters with spaces): This RC joins groups sharing 
interest and research in translational medicine ofinflammation and immunology. The groups are situated at 
the Transplantation Laboratory and altogether the RC has high-quality equipment and wide spectrum of 
methodology at their disposal. Professor Renkonen’s group has focused on the glycobiology of 
inflammatory diseases and has implemented systems biology approaches in investigations of the 
mechanism of type I allergic reactions. The research focus in Docent Lokki’s group is the influence of the 
MHC genes on prolonged inflammatory reactions predisposing tissues to various diseases, especially 
atherosclerosis and recurrent infectious diseases. MHC genes are also the main determinants regulating the 
inflammatory reactions in tissue transplantations. Docent Lemström’s group has 
investigated the inflammation and immunology of transplant rejection showing interplay of inflammation, 
angiogenesis and arteriosclerosis in transplanted grafts. Since 
immunological aspects have emerged important in the treatment of cancer, Research professor 
Hemminki’s group has studied how to break the immunological tolerance of a 
tumor by manipulating the immune system with oncolytic adenoviruses. We all research inflammation and 
immunology, with a different approach to the problems. The groups have high ability to work 
independently. However, together we 
have the background for both basic and clinical research and share the aim to quickly translate the results 
of basic research into the clinical setting. Renkonen’s group has 
extensive experience in basic immunology and human research while Lemström’s unit has strong 
experience and facilities in animal research. Both, however, lack the ability to study the genetical aspect 
which will be complemented by Lokki’s group. Hemminki’s group has strong basic research effort into the 
immunology of gene therapy and utilization of immunostimulatory approaches for the treatment of cancer. 
In the future, RC will allow joint doctoral training without group-to-group borders to cross gaining the 
advantage of both full-time laboratory workers and doctors working mainly in clinics. This facilitates 
translational medicine. 
1 RESPONSIBLE PERSON 
2 DESCRIPTION OF THE PARTICIPATING RESEARCHER COMMUNITY (RC) 
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INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE 
UNIVERSITY OF HELSINKI  
 
RC-SPECIFIC STAGE 1 MATERIAL (registration form) 
 
 
 
 
Main scientific field of the RC’s research: medicine, biomedicine and healt sciences 
RC's scientific subfield 1: Immunology 
RC's scientific subfield 2: Genetics and Heredity 
RC's scientific subfield 3: Biochemistry and Molecular Biology 
RC's scientific subfield 4: --Select-- 
Other, if not in the list: Translational Medicine 
 
 
Participation category: 2. Research of the participating community is of high quality, but the community in 
its present composition has yet to achieve strong international recognition or a clear break-through 
Justification for the selected participation category (MAX. 2200 characters with spaces):  All the groups 
that are to be combined have a history of high-quality international 
research in their respective fields. However, as international competition is getting 
harder, it is essential to form larger and stronger units in order to keep up the present 
standards and improve them. We believe that the new composition in this RC will give 
us sufficient strength to gain international recognition. More importantly, the enhanced 
co-operation will help us with our main aim, that is translating our basic research into 
working clinical treatments. 
 
 
Public description of the RC's research and doctoral training (MAX. 2200 characters with spaces): Prof. 
Renkonen’s group has focused on the glycobiology of inflammatory diseases, the research focus in Docent 
Lokki’s group is the influence of the MHC genes on prolonged inflammatory reactions predisposing tissues 
to various diseases.Docent Lemström’s group has investigated the inflammation and immunology of 
transplant rejection showing interplay of inflammation, angiogenesis and arteriosclerosis and since 
immunological aspects have emerged important in the treatment of cancer, Research 
professor Hemminki’s group has studied how to break the immunological tolerance of a tumor.  
Renkonen’s group: Out of the twelve PhD thesis this group has accomplished since 1993, two fall into the 
evaluation period (JuhaPekka Pitkänen 2005, Jaana Niittymäki, 2007). We have now 4 doctoral students 
(Sakari Joenväärä, Niina Tohmola, Ville Parviainen and Hannu Peltoniemi). Lemström’s group: During the 
evaluation period we have finished one doctoral thesis (Antti Nykänen, 2007) and have now 9 doctoral 
students of whom four are at an advanced stage and should finish their theses during 2011-12 (Rainer 
Krebs, Raimo Tuuminen, Jukka Rintala and Mikko Keränen) and five at an earlier stage (Jussi Ropponen, 
Simo Syrjälä, Alireza Raissadati, Niina Malmström, and Sini Rintala) who 
should finish their theses by 2013. Hemminki’s group:eight PhD thesis have been finished in our group 
during the evaluation period (Tanja Hakkarainen, Gerd Bauerschmitz, Merja Särkioja, Kilian Guse, Mari Raki, 
3 SCIENTIFIC FIELDS OF THE RC 
4 RC'S PARTICIPATION CATEGORY 
5 DESCRIPTION OF THE RC'S RESEARCH AND DOCTORAL TRAINING 
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INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE 
UNIVERSITY OF HELSINKI  
 
RC-SPECIFIC STAGE 1 MATERIAL (registration form) 
 
 
Lotta Kangasniemi, Tuuli Ranki, Iulia Diaconu) and there is still one dissertation coming in December 2010 
(Joao Dias). At the moment we have 11 doctoral students at different stages of their thesis. Lokki’s group: 
One PhD thesis has been finished during the evaluation period (Anil Palikhe, 2008)and we have now 4 
doctoral students (Riitta Paakkanen, Annika Wennerström, Marja Marchesani,Johanna Nokelainen)at 
different stages of their thesis. We have had approximately 26 students in National Graduate Schools and 
also been involved in the administration and development of these graduate schools.Risto Renkonen is 
currently heading one of them(GGS i.e. Glycoscience Graduate School). 
Significance of the RC's research and doctoral training for the University of Helsinki (MAX. 2200 
characters with spaces): ID-TM group is a newly established research community. We have a large variety 
of 
methodologies and knowledges and the groups produce high quality research. Combining 
our specialities in more intense collaboration will produce a strong research community 
in the field of inflammatory medicine and biology which has been nominated one of the 
main focuses in the future collaborative studies between the faculty of Medicine at the 
University of Helsinki and the Helsinki University Central Hospital. Strong national and 
international recognition creates possibilities to focus and increase doctoral training in 
the field of inflammatory diseases. This is needed at many branches of medicine, e.g. 
neurology, ophthalmology, oncology and cardiology. 
Keywords: Inflammation, Diseases, Translational Medicine, Immunology, Genetics, Biomedicine, Health 
Sciences 
 
 
Justified estimate of the quality of the RC's research and doctoral training at national and international 
level during 2005-2010 (MAX. 2200 characters with spaces): During the evaluation period Renkonen’s 
group had 20, Lemström’s group had 23, 
Lokki’s group had 20 and Hemminki’s group had 66 peer reviewed publications. 
All the groups have internationally high quality publications. Many members of this 
RC are scientifically award-winning, they have organized courses and lectures at the 
University of Helsinki, they have administrative experience, they are reviewers of grants, 
dissertations and docentships, they have been as an opponent on dissertations, and as 
referees and editorial board members for international scientific journals. 
Comments on how the RC's scientific productivity and doctoral training should be evaluated (MAX. 2200 
characters with spaces): Based on high-level of publications. 
6 QUALITY OF RC'S RESEARCH AND DOCTORAL TRAINING 
LIST OF RC MEMBERS
NAME OF THE RESEARCHER COMMUNITY: Inflammatory Diseases- towards Translational Medicine
RC-LEADER ML. Lokki
CATEGORY 2
Last name First name
PI-status 
(TUHAT, 
29.11.2010)
Title of research and 
teaching personnel Affiliation 
1 Lokki Marja-Liisa X Research Director
Faculty of Medicine, Haartman Institute, Transplantation 
Laboratory
2 Palikhe Anil Doctoral candidate
Faculty of Medicine, Haartman Institute, Transplantation 
Laboratory
3 Paakkanen Riitta Doctoral candidate
Faculty of Medicine, Haartman Institute, Transplantation 
Laboratory
4 Wennerström Annika Doctoral candidate
Faculty of Medicine, Haartman Institute, Transplantation 
Laboratory
5 Marchesani Marja Doctoral candidate
Faculty of Medicine, Haartman Institute, Transplantation 
Laboratory
6 Nokelainen Johanna Doctoral candidate
Faculty of Medicine, Haartman Institute, Transplantation 
Laboratory
7 Sinisalo Juha Senior Researcher
Faculty of Medicine,Division of Cardiology, Helsinki University 
Central Hospital
8 Lemström Karl X Senior Researcher
Faculty of Medicine, Haartman Institute, Transplantation 
Laboratory
9 Koskinen Petri X Senior Researcher
Faculty of Medicine, Haartman Institute, Transplantation 
Laboratory
10 Nykänen Antti Postdoctoral Researcher
Faculty of Medicine, Haartman Institute, Transplantation 
Laboratory
11 Tikkanen Jussi Postdoctoral Researcher
Faculty of Medicine, Haartman Institute, Transplantation 
Laboratory
12 Savikko Johanna Postdoctoral Researcher
Faculty of Medicine, Haartman Institute, Transplantation 
Laboratory
13 Tuuminen Raimo Doctoral candidate
Faculty of Medicine, Haartman Institute, Transplantation 
Laboratory
14 Krebs Rainer Doctoral candidate
Faculty of Medicine, Haartman Institute, Transplantation 
Laboratory
15 Syrjälä Simo Doctoral candidate
Faculty of Medicine, Haartman Institute, Transplantation 
Laboratory
16 Ropponen Jussi Doctoral candidate
Faculty of Medicine, Haartman Institute, Transplantation 
Laboratory
17 Raissadati Alireza Doctoral candidate
Faculty of Medicine, Haartman Institute, Transplantation 
Laboratory
18 Keränen Mikko Doctoral candidate
Faculty of Medicine, Haartman Institute, Transplantation 
Laboratory
19 Malmström Niina Doctoral candidate
Faculty of Medicine, Haartman Institute, Transplantation 
Laboratory
20 Rintala Jukka Doctoral candidate
Faculty of Medicine, Haartman Institute, Transplantation 
Laboratory
21 Rintala Sini Doctoral candidate
Faculty of Medicine, Haartman Institute, Transplantation 
Laboratory
22 Hemminki Akseli X senior researcher
Faculty of Medicine, Molecular Cancer Biology Program & 
Haartman Institute & Transplantation Laboratory & Finnish 
Institute for Molecular Medicine
23 Kanerva Anna senior researcher
Faculty of Medicine, Molecular Cancer Biology Program & 
Haartman Institute & Transplantation Laboratory & Finnish 
Institute for Molecular Medicine
24 Pesonen Sari senior researcher
Faculty of Medicine, Molecular Cancer Biology Program & 
Haartman Institute & Transplantation Laboratory & Finnish 
Institute for Molecular Medicine
25 Cerullo Vincenzo senior researcher
Faculty of Medicine, Molecular Cancer Biology Program & 
Haartman Institute & Transplantation Laboratory & Finnish 
Institute for Molecular Medicine
26 Escutenaire Sophie senior researcher
Faculty of Medicine, Molecular Cancer Biology Program & 
Haartman Institute & Transplantation Laboratory & Finnish 
Institute for Molecular Medicine
27 Kangasniemi Lotta postdoctoral researcher
Faculty of Medicine, Molecular Cancer Biology Program & 
Haartman
Institute & Transplantation Laboratory & Finnish Institute for 
Molecular Medicine
28 Ranki Tuuli postdoctoral researcher
Faculty of Medicine, Molecular Cancer Biology Program & 
Haartman Institute & Transplantation Laboratory & Finnish 
Institute for Molecular Medicine
29 Diaconu Iulia postdoctoral researcher
Faculty of Medicine, Molecular Cancer Biology Program & 
Haartman Institute & Transplantation Laboratory & Finnish 
Institute for Molecular Medicine
30 Dias João Doctoral candidate
Faculty of Medicine, Molecular Cancer Biology Program & 
Haartman Institute & Transplantation Laboratory & Finnish 
Institute for Molecular Medicine
31 Ahonen Marko Doctoral candidate
Faculty of Medicine, Molecular Cancer Biology Program & 
Haartman Institute & Transplantation Laboratory & Finnish 
Institute for Molecular Medicine
32 Koski Anniina Doctoral candidate
Faculty of Medicine, Molecular Cancer Biology Program & 
Haartman Institute & Transplantation Laboratory & Finnish 
Institute for Molecular Medicine
33 Liikanen Ilkka Doctoral candidate
Faculty of Medicine, Molecular Cancer Biology Program & 
Haartman Institute & Transplantation Laboratory & Finnish 
Institute for Molecular Medicine
34 Nokisalmi Petri Doctoral candidate
Faculty of Medicine, Molecular Cancer Biology Program & 
Haartman Institute & Transplantation Laboratory & Finnish 
Institute for Molecular Medicine
35 Rajecki Maria Doctoral candidate
Faculty of Medicine, Molecular Cancer Biology Program & 
Haartman Institute & Transplantation Laboratory & Finnish 
Institute for Molecular Medicine
36 Hemminki Otto Doctoral candidate
Faculty of Medicine, Molecular Cancer Biology Program & 
Haartman Institute & Transplantation Laboratory & Finnish 
Institute for Molecular Medicine
37 Rouvinen-Lagerström Noora Doctoral candidate
Faculty of Medicine, Molecular Cancer Biology Program & 
Haartman Institute & Transplantation Laboratory & Finnish 
Institute for Molecular Medicine
38 Parviainen Suvi Doctoral candidate
Faculty of Medicine, Molecular Cancer Biology Program & 
Haartman Institute & Transplantation Laboratory & Finnish 
Institute for Molecular Medicine
39 Bramante Simona Doctoral candidate
Faculty of Medicine, Molecular Cancer Biology Program & 
Haartman Institute & Transplantation Laboratory & Finnish 
Institute for Molecular Medicine
40 Hirvinen Mari Doctoral candidate
Faculty of Medicine, Molecular Cancer Biology Program & 
Haartman Institute & Transplantation Laboratory & Finnish 
Institute for Molecular Medicine
41 Renkonen Risto X
Professor, Dean of the 
Faculty of Medicine
Faculty of Medicine, Haartman Institute, Transplantation 
Laboratory
42 Joenväärä Sakari Doctoral candidate
Faculty of Medicine, Haartman Institute, Transplantation 
Laboratory
43 Parviainen Ville Doctoral candidate
Faculty of Medicine, Haartman Institute, Transplantation 
Laboratory
44 Tohmola Niina Doctoral candidate
Faculty of Medicine, Haartman Institute, Transplantation 
Laboratory
45 Peltoniemi Hannu Doctoral candidate
Faculty of Medicine, Haartman Institute, Transplantation 
Laboratory
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Name of the RC’s responsible person: Lokki, Maisa 
E-mail of the RC’s responsible person:   
Name and acronym of the participating RC: Inflammatory Diseases- towards Translational Medicine, ID-
TM-group 
The RC’s research represents the following key focus area of UH: 6. Kliininen tutkimus – Clinical research 
Comments for selecting/not selecting the key focus area: This RC integrates both high level basic 
immunological and genetic research with clinically relevant animal models and finally clinical research. The 
combination allows the RC to quickly translate our findings in basic research to animal and clinical tests. All 
four groups of this RC have published both basic research and clinical papers during the evaluation period. 
The RC also consists of both full-time scientists and clinicians which facilitates translational research. 
 
 
 Description of the RC’s research focus, the quality of the RC’s research (incl. key research 
questions and results) and the scientific significance of the RC’s research for the research 
field(s).  
The Faculty of Medicine, University of Helsinki, Finland, has defined its primary research foci together 
with the Helsinki University Central Hospital (HUS). One of these is infections and inflammation and thus 
our work aiming to understand the basic mechanisms of immunological diseases in human patients falls 
well into this scope. This RC combines several distinct approaches to investigate immunological diseases 
in humans and are listed below: 
 
Professor Renkonen’s group: 
We apply a systems biology approach, including several large scale data collections, such as various 
microscopy techniques, transcriptomics, proteomics, interactomics pathway analysis etc. All these 
measurements and data analyses help us to understand the basic mechanisms of immunological 
diseases in human patients. Our novel observations in acute allergy and the new active role of 
epithelium in the pathogenesis of this disease have generated several publications and both national 
and international recognition: The Medix Prize 2010 for the best medical paper in Finland and European 
Academy of Allergy and Clinical Immunology (EAACI) selected this work as one of the few “Hot topic 
Lectures” at their annual meeting with 5000 participants (2009). 
 
Docent Lokki’s group:  
Inflammation has a central role also in the pathophysiology of acute coronary syndrome but the 
ultimate reasons for the inflammation remain unrevealed. The system that regulates inflammation, 
immunity and defensive mechanisms against microbes lies in big part in the Major Histocompatibility 
Complex (MHC) region and is associated with hundreds of diseases, including most if not all, 
autoimmune diseases. Our focus is to study to role of MHC genes in inflammatory, infectious and 
autoimmune diseases like coronary heart disease, severe and recurrent upper respiratory infections and 
sarcoidosis. We have built tests to study copy number variation of MHC genes which are also in use for 
diagnostic purposes, and use CNV information together with single nucleotide polymorphism analyses. 
We have collected a cohort of 5000 patients’ samples for to study contemporary trends, risk factors, 
genetics and epigenetics for coronary heart disease. The material has been used as a replication cohort 
BACKGROUND INFORMATION 
1 FOCUS AND QUALITY OF RC'S RESEARCH (MAX. 8800 CHARACTERS WITH SPACES) 
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in several large GWA-consortiums published in top biomedical journals (Nature Genetics, Nature, Lancet 
etc.). 
 
Docent Lemström’s group: 
Solid organ transplantation is the final treatment option in severe heart, lung, and kidney diseases when 
all other therapeutic approaches have failed. Although treatment of patients receiving solid organ 
transplants has markedly improved in the last years, chronic allograft rejection remains an important 
problem and cause of mortality and morbidity in these patients. We have developed animal models for 
investigating chronic allograft rejection in heart, lung, and kidney transplantation. Our work 
concentrates in uncovering new pathways that are biologically relevant in the development of chronic 
allograft rejection and targeting these pathways with specific drugs. Our work has been published in 
leading clinical journals of the respective fields (Circulation, American Journal of Respiratory and Critical 
Care Medicine etc). Our main aim has always been to translate our results of animal studies to the clinic. 
This is facilitated by the fact that our group consists of both full-time researchers as well as clinicians 
working in clinical transplantation units in the Helsinki University Central Hospital. Currently, we have an 
ongoing pilot clinical trial where simvastatin is administered to organ donors in order to limit early 
ischemia-reperfusion injury after transplantation. 
 
Research Professor Hemminki’s group: 
Oncolytic adenovirus based therapy represents a novel treatment approach for cancer refractory to 
conventional therapies. Adenoviruses are quite immunogenic and recent preclinical and clinical 
evidence suggests that anti-tumor efficacy is partially mediated by the immune response. However, the 
anti-viral immune reaction is not strong enough to result in tumor eradication. Therefore, to boost this 
effect, arming the virus with immunostimulatory molecules is an attractive prospect.  
We have studied extensively the use of oncolytic adenoviruses in treatment of cancer. During the last 
couple of years, we have focused mainly on oncolytic adenoviruses expressing immunostimulatory 
molecules such as GM-CSF, CD40L and CTLA-4. We have published dozens of preclinical articles in 
international peer-reviewed scientific publication series. More importantly, we have been able to 
translate this approach to the clinic. In collaboration with University spin-off company Oncos 
Therapeutics over 230 cancer patients who have already undergone all routine modalities have been 
treated with oncolytic viruses, including four different GM-CSF expressing viruses and a CD40L 
expressing virus. Our group has been analyzing patient data yielding several clinical publications. In co-
operation with Oncos Therapeutics, the first clinical trial with GM-CSF expressing virus CGTG-102 will 
start during 2011. 
 Ways to strengthen the focus and improve the quality of the RC’s research. 
Although all the different groups that form this RC share their interest in inflammation, the groups have 
a different background and have used somewhat different approaches to study inflammation. Forming 
this RC will allow us to share our technological expertise with one another providing us new tools and 
possibilities in our research. 
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  How is doctoral training organised in the RC? Description of the RC’s principles for recruitment and 
selection of doctoral candidates, supervision of doctoral candidates, collaboration with faculties, 
departments/institutes, and potential graduate schools/doctoral programmes, good practises and 
quality assurance in doctoral training, and assuring good career perspectives for the doctoral 
candidates/fresh doctorates.  
All groups in this RC actively advertise and promote our RC during lectures which we give to students. 
Also, clinicians actively recruit medical students and resident fellows from the clinic. Our RC has doctoral 
students from several graduate schools. We also have a good reputation amongst the students and our 
own doctoral students form our most efficient and valuable tool for recruitment.  
 
In addition, this RC benefits from the broad range of technology at our disposal as our research ranges 
from basic immunological research to microsurgery and to clinical research, and thus our RC has so far 
been able to recruit doctoral students to meet our needs. The selection process consists of an interview 
and a possible test period (i.e. pro gradu work) before commitment to a PhD program.   
 
- supervision of doctoral candidates. 
Professor Renkonen’s group has trained 12 MD/PhD thesis students during the last 20 years and three 
of them are within in the period 2005-2010. 
Docent Lokki’s group has trained six MD/PhD students and one has graduated during the period 2005-
2010.  
Docent Lemström’s group has trained four MD/PhD students and one has graduated during the period 
2005-2010. 
Research Professor Hemminki’s group has trained 11 PhD or MD/PhD students during last nine years 
and nine of them graduated during the evaluation period 2005-2010. 
 
- collaboration with faculties, departments/institutes, and potential graduate schools/doctoral 
programmes. 
Professor Renkonen’s group: Out of the 12 theses, one was done in collaboration with TKK/Aalto 
University, seven are joint projects between the Faculty of Bioscience/Biochemistry, even though 
professor Renkonen is the sole supervisor of them and four are solely from the Faculty of Medicine. 
Professor Renkonen is one of the founders and the current director of the National Glycoscience 
Graduate School (GGS) sponsored by the Academy of Finland. 
Docent Lokki’s group: Three PhD students are solely from the Faculty of Medicine, two are from both 
the Faculties of Bioscience and Medicine and one from the programme offered jointly by the University 
of Helsinki and Aalto University School of Science and Technology. One student belongs to the LERU 
doctoral programme (League of European Research Universities, joint PhD Program in biomedicine 
between University of Helsinki and Karolinska Institutet) and one student to the Helsinki Biomedical 
Graduate School.  
Docent Lemström’s group: One post-doctoral fellow is arriving this year from the University of Freiburg. 
Our PhD students are from the Faculty of Medicine mainly due to the clinical nature of our work.  
Research professor Hemminki’s group: Out of the nine doctoral students graduated during 2005-2010 
four held a position in Helsinki Biomedical Graduate School (one in MD/PhD Program which is a joint 
program between the Biomedical Graduate School and the Faculty of Medicine) and one had position in 
2 PRACTISES AND QUALITY OF DOCTORAL TRAINING (MAX. 8800 CHARACTERS WITH SPACES) 
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Graduate School in Biotechnology and Molecular Biology. One of the theses was a joint project with 
Department of Biotechnology and Molecular Medicine, University of Kuopio and one with Department 
of Obstetrics and Gynecology and Department of Oncology, Helsinki University Central Hospital. All of 
the theses were done in collaboration with HUSLAB, Helsinki University Central Hospital and Molecular 
Cancer Research Program, Faculty of Medicine, University of Helsinki. Eight of them were also made in 
cooperation of Finnish Institute of Molecular Medicine. At the moment we have 10 graduate students 
out of which one holds position in The National Graduate School of Clinical Investigation and one just 
received a position in Helsinki Graduate Program in Biotechnology and Molecular Biology. 
 
- good practises and quality assurance in doctoral training. 
The doctoral students have a thesis plan, and a follow-up group with yearly meetings. The students 
actively participate both at attending the lectures and also in arranging one or two annual meetings with 
some 120 participants. All students participate in both national and international courses and meetings 
and supervise younger students. We also support our students to lecture both in national educational 
symposiums as well as abroad.  
 
- assuring good career perspectives for the doctoral candidates/fresh doctorates. 
In December 2009 we arranged a symposium entitled “Carrier opportunities after PhD” with more 100 
participants at the Haartman Institute. We also encourage and actively help the students to build wide 
contacts with different national research groups and to contact international groups for collaborations.  
The new RC is sufficiently large to allow us to provide work for many postdoctoral fellows. For physician 
students, a PhD degree assists in work application and is of special assistance in applying for positions in 
those specialities where inflammation is central, such as clinical microbiology, oncology, transplantation 
medicine, infectious diseases etc. 
 RC’s strengths and challenges related to the practises and quality of doctoral training, and the actions 
planned for their development. 
We are good in training PhD students. We need still to put more emphasis on the broad teaching of 
techniques both in the wet-lab as well as in in silico approaches so that the new generation can readily 
tackle the system level problems of clinically relevant medical problems. Our strength is to have 
students with different basic knowledge like genetics, biochemistry, clinical medicine, bioinformatics 
and statistics. The new RC will enable us to hold joint training sessions where we can teach the students 
a broad range of methodology. 
 
 
 Description of how the RC interacts with and contributes to the society (collaboration with public, 
private and/or 3rd sector).  
As previously pointed out the University of Helsinki and Helsinki University Central hospital had defined 
the focus areas, which have a significant impact in the society. As infections and inflammation are one of 
these foci and we have a good tradition in carrying out research within this field we can strongly 
participate into the University of Helsinki’s efforts on the third sector in this area. 
We not only provide new MD/PhD but also specialists in the field of clinical microbiology who all will 
serve jointly at the University of Helsinki and Helsinki University Central Hospital to diagnose and treat 
patients in the field of infections and inflammation. Furthermore, many of our researchers and doctoral 
students are working also in clinical positions. The importance of clinician-researchers has been lately 
recognized to be central for transferring basic research findings into clinical use and is a clear advantage 
3 SOCIETAL IMPACT OF RESEARCH AND DOCTORAL TRAINING (MAX. 4400 CHARACTERS WITH SPACES) 
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of this RC. All four research groups in this RC already perform both basic as well as clinical research 
allowing quick translation of our basic research findings into the clinical setting.  
In addition to the research work related to infectious and inflammatory diseases, we are running a 
diagnostic laboratory offering gene tests to study and evaluate patients' susceptibility to infectious, 
inflammatory and autoimmune diseases. As an internationally accredited laboratory (European 
Federation for Immunogenetics) we have developed several gene tests and also use high quality 
commercial tests to analyse MHC (major histocompatibility complex)-related genes. 
 Ways to strengthen the societal impact of the RC’s research and doctoral training. 
We still need to put more effort on the most common inflammatory diseases and try to find novel 
diagnostic and treatment modalities for them. Integration of the four different research groups will both 
strengthen our capability for research as well as our ability to train doctoral students when we pool our 
knowledge into one larger unit. 
 
 
 
 Description of the RC’s research collaborations and joint doctoral training activities and how the RC 
has promoted researcher mobility.  
Our RC has research collaborations with several clinics of the Helsinki University Hospital such as 
divisions of infectious diseases, cardiothoracic surgery, pulmology, cardiology, ophthalmology, and 
neurology and collaborates with research groups in Biomedicum Helsinki and National Institute for 
Health and Welfare. Docent Lokki is a member of the management committee of COST action BM0803 “ 
a European network of the HLA diversity for histocompatibility, clinical transplantation, epidemiology 
and population genetics (HLA-NET)” which also organizes meetings, short-term scientific visits and 
international training schools for students. 
 RC’s strengths and challenges related to research collaboration and researcher mobility, and the 
actions planned for their development. 
This RC is nationally very strong in the field of immunological research. However, our aim is to increase 
international exchange of doctoral students and postdoctoral fellows and several of our researchers 
have applied for research fellowships abroad. We already have a wide base of collaborators both 
nationally and internationally but we continuously aspire to increase this collaboration. We actively 
encourage international exchange of researchers and doctoral students and will receive a research 
fellow from the University of Freiburg in 2011 and one of our researchers is going to the University of 
Toronto in 2012. This international exchange will open up possibilities for further researcher mobility in 
the future. 
 
 
 Description of the operational conditions in the RC’s research environment (e.g. research 
infrastructure, balance between research and teaching duties).  
Research infrastructure is currently suitable with updated laboratory facilities and a fully operational 
unit for animal studies. We participate in the running of Meilahti Mass spectrometry Core unit and will 
update our Q-TOF instrument in January 2012 with funds already allocated to us from Biocentrum 
Finland and the University of Helsinki (500 000 €).  
 
4 INTERNATIONAL AND NATIONAL (INCL. INTERSECTORAL) RESEARCH COLLABORATION AND RESEARCHER 
MOBILITY (MAX. 4400 CHARACTERS WITH SPACES) 
5 OPERATIONAL CONDITIONS (MAX. 4400 CHARACTERS WITH SPACES) 
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Professor Renkonen is the Dean of the Medical Faculty 2010-2013 and thus has somewhat more limited 
resources for research during the coming years. However, Professor Renkonen’s group still has 4 PhD 
students who all are expected to complete their studies with the next two years. Docent Lokki is in a 
full-time position. Many of our clinician-researchers have varying duties in the clinic but have been 
awarded personal grants to perform research full-time for several months a year. Docent Lemström has 
been elected as a Professor of Transplantation Medicine and this position will allow more full-time 
research than before. Research Professor Akseli Hemminki holds K. Albin Johansson Research 
Professorship (Finnish Cancer Institute) which enables full-time research free from clinical duties. 
 
All group leaders and several other researchers participate actively in teaching on the basic courses with 
the Faculties of Medicine and Biosciences as well as at the Aalto University. 
 RC’s strengths and challenges related to operational conditions, and the actions planned for their 
development. 
There are no severe challenges related to the operational conditions of the RC. Our financial situation is 
solid and we have the necessary facilities at our disposal. Professor Renkonen has limited time resources 
as long as he continues in the position of Dean at the Faculty of Medicine (2010-2013) but Docent Lokki 
and Professor Hemminki are full-time scientists and Docent Lemström will have more research time with 
his appointment as a Research Professor. 
 
 
 
 Description of the execution and processes of leadership in the RC, how the management-related 
responsibilities and roles are distributed in the RC and how the leadership- and management-related 
processes support high quality research, collaboration between principal investigators and other 
researchers in the RC, the RC’s research focus and strengthening of the RC’s know-how.  
The Faculty of Medicine, University of Helsinki, Finland, has defined its primary research focuses 
together with the University Central Hospital (HUS). One of these is infections and inflammations and 
thus our work aiming to understand the basic mechanisms of immunological diseases in human patients 
falls well into this scope. 
 
The RC has four principal investigators heading their research groups and the groups have organized 
their own personnel and working managements. The principal investigators will hold regular meetings to 
discuss areas of cooperation. The groups of this RC will actively support cooperation between 
researchers of the different groups and common training sessions and seminars will be held on a regular 
basis. The cooperation enables more efficient use of resources and laboratory apparel and will thereby 
reduce research costs. Our aim is to reduce the threshold between the different groups to a minimum to 
allow spread of information and easy consultation and strengthening of the know-how in our RC. 
 RC’s strengths and challenges related to leadership and management, and the actions planned for 
developing the processes. 
Our RC has four principal investigators that have known each other for years and have already 
cooperated with one another before the forming of this RC. This earlier cooperation sets a fruitful basis 
for closer cooperation in the following years aiming at co-application for new grants and joint doctoral 
students between the different groups. 
 
 
6 LEADERSHIP AND MANAGEMENT IN THE RESEARCHER COMMUNITY (MAX. 4400 CHARACTERS WITH SPACES) 
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 Listing of the RCs external competitive funding, where: 
- the funding decisions have been made during 1.1.2005-31.12.2010, and 
- the administrator of the funding is/has been the University of Helsinki 
 
 Academy of Finland (AF) - total amount of funding (in euros) AF has decided to allocate to the RC 
members during 1.1.2005-31.12.2010: 1330000 
 
 Finnish Funding Agency for Technology and Innovation (TEKES) - total amount of funding (in euros) 
TEKES has decided to allocate to the RC members during 1.1.2005-31.12.2010:  
 
 European Union (EU) - total amount of funding (in euros) EU has decided to allocate to the RC members 
during 1.1.2005-31.12.2010: 690000 
 
 European Research Council (ERC) - total amount of funding (in euros) ERC has decided to allocate to the 
RC members during 1.1.2005-31.12.2010: 1620000 
 
 International and national foundations – names of international and national foundations which have 
decided to allocate funding to the RC members during 1.1.2005-31.12.2010, and the amount of their 
funding (in euros).  
- names of the foundations: Cancer Organizations, Sigrid Juselius Foundation, Schering Research 
Foundation and Finnish Oncology Association, Sigrid Juselius Foundation, Foundation for 
Cardiovascular Research, Nummela Hospital Research Society 
- total amount of funding (in euros) from the above-mentioned foundations: 1640000 
 
 Other international funding - names of other international funding organizations which have decided to 
allocate funding to the RC members during 1.1.2005-31.12.2010, and the amount of their funding (in 
euros). 
- names of the funding organizations: American Society of Clinical Oncology, Wellcome Trust Sanger 
Institute, Roche Organ Transplantation Research Foundation 
- total amount of funding (in euros) from the above-mentioned funding organizations: 290000 
 
 Other national funding (incl. EVO funding and Ministry of Education and Culture funded doctoral 
programme positions) - names of other national funding organizations which have decided to allocate 
funding to the RC members during 1.1.2005-31.12.2010, and the amount of their funding (in euros). 
- names of the funding organizations: EVO and University of Helsinki Funds 
- total amount of funding (in euros) from the above-mentioned funding organizations: 2100000 
 
 
 
 Description of the RC’s future perspectives in respect to research and doctoral training. 
All four groups have a strong PhD program. Most of the current students will finalize their PhD during 
the time period of 2011-2013 in their own respective groups. New students will be recruited to start 
new projects. Our strategy is to actively support group-to-group cooperation in training new doctoral 
students as this will serve to deepen and strengthen our RC. 
7 EXTERNAL COMPETITIVE FUNDING OF THE RC 
8 RC’S STRATEGIC ACTION PLAN FOR 2011–2013 (MAX. 4400 CHARACTERS WITH SPACES) 
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All prinicipal investigators equally contributed to the compilation of this material. 
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1 Analysis of publications 
 
- Associated person is one of Marja-Liisa Lokki ,  Anil Palikhe , Riitta Paakkanen , Marja 
Marchesani , Juha-Pekka Sinisalo, Karl Birger Lemström ,  Petri Koskinen ,  Antti 
Nykänen ,  Jussi Tikkanen ,  Minna Johanna Savikko ,  Rainer Krebs , 
 Mikko Antti Ilmari Keränen ,  Jukka Martti J Rintala ,  Sini Rintala , 
 Akseli Eetu Hemminki ,  Anna-Maija Kanerva ,  ,  Sari Pesonen , 
 Vincenzo Cerullo ,  Sophie Escutenaire ,  Lotta Kangasniemi , 
 ,  Tuuli Ranki ,  ,  Iulia Diaconu , , 
 Joao Daniel Afonso De Carvalho Dias ,  Marko Tapio Ahonen , Anniina Kaisa Elina Koski , 
 Ilkka Liikanen , Petri Nokisalmi ,  Maria Karolina Rajecki ,  Otto 
Hemminki , Suvi Parviainen , Risto Renkonen , Sakari Joenväärä , 
 Ville Parviainen ,  Niina Johanna Tohmola ,  
 
Publication year 
Publication type 2005 2006 2007 2008 2009 2010 
Total Count 2005 - 
2010 
A1 Refereed journal article 25 30 24 23 37 40 179 
A2 Review in scientific journal 5 4 2 2 2 2 17 
A3 Contribution to book/other compilations (refereed) 2   4   6 
A4 Article in conference publication (refereed)    2 7  9 
B1 Unrefereed journal article 2 1   5 1 9 
B3 Unrefereed article in conference proceedings    1   1 
D1 Article in professional journal      1 1 
E1 Popular article, newspaper article      1 1 
 
 
 
ID-TM/Lokki 
 
 
2 
 
INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE 
UNIVERSITY OF HELSINKI  
 
RC-SPECIFIC TUHAT COMPILATIONS OF PUBLICATIONS DATA 2005-2010 
 
 
2 Listing of publications 
A1 Refereed journal article 
2005 
Alazzouzi, H, Alhopuro, P, Salovaara, R, Sammalkorpi, H, Järvinen, HJ, Mecklin, J, Hemminki, A, Schwartz, S, Aaltonen, LA, Arango, D 
2005, 'SMAD4 as a prognostic marker in colorectal cancer', Clinical Cancer Research, vol 11, no. 7, pp. 2606-2611. 
Alhopuro, P, Alazzouzi, H, Sammalkorpi, H, Davalos, V, Salovaara, R, Hemminki, A, Järvinen, HJ, Mecklin, J, Schwartz, S, Aaltonen, 
LA, Arango, D 2005, 'SMAD4 levels and response to 5-fluorouracil in colorectal cancer',  Clinical Cancer Research, vol 11, no. 17, pp. 
6311-6316. 
Arango, D, Laiho, P, Kokko, A, Alhopuro, P, Sammalkorpi, H, Salovaara, R, Nicorici, D, Hautaniemi, S, Alazzouzi, H, Mecklin, J, 
Järvinen, HJ, Hemminki, AE, Astola, J, Schwartz, S, Aaltonen, LA 2005, 'Gene-expression profiling predicts recurrence in Dukes' C 
colorectal cancer', Gastroenterology, vol 129, no. 3, pp. 874-884. 
Hakkarainen, T, Wahlfors, T, Meriläinen, O, Loimas, S, Hemminki, A, Wahlfors, J 2005, 'VP22 does not significantly enhance enzyme 
prodrug cancer gene therapy as a part of a VP22-HSVTk-GFP triple fusion construct', Journal of Gene Medicine, vol 7, no. 7, pp. 898-
907. 
Helanterä, I, Loginov, R, Koskinen, P, Törnroth, T, Grönhagen-Riska, C, Lautenschlager, I 2005, 'Persistent cytomegalovirus infection is 
associated with increased expression of TGF-beta1, PDGF-AA and ICAM-1 and arterial intimal thickening in kidney allografts',  
Nephrology, Dialysis, Transplantation, vol 20, pp. 790-796. 
Kanerva, A, Zinn, KR, Peng, K, Ranki, T, Kangasniemi, L, Chaudhuri, TR, Desmond, RA, Wang, M, Takayama, K, Hakkarainen, T, 
Alfthan, HV, Stenman, U, Curiel, DT, Hemminki, A 2005, 'Noninvasive dual modality in vivo monitoring of the persistence and potency of 
a tumor targeted conditionally replicating adenovirus',  Gene Therapy (Basingstoke), vol 12, no. 1, pp. 87-94. 
Kanerva, A, Hemminki, A 2005, 'Adenoviruses for treatment of cancer', Annals of Medicine, vol 37, pp. 33-43. 
Krebs, R, Tikkanen, JM, Nykänen, AI, Wood, J, Jeltsch, M, Ylä-Herttuala, S, Koskinen, PK, Lemström, K 2005, 'Dual role of vascular 
endothelial growth factor in experimental obliterative bronchiolitis',  American Journal of Respiratory and Critical Care Medicine, vol 
171, no. 12, pp. 1421-1429. 
Lehto, JT, Lemström, K, Halme, M, Lappalainen, M, Lommi, J, Sipponen, J, Harjula, A, Tukiainen, P, Koskinen, PK 2005, 'A prospective 
study comparing cytomegalovirus antigenemia, DNAemia and RNAemia tests in guiding pre-emptive therapy in thoracic organ 
transplant recipients', Transplant International, vol 18, pp. 1318-1327. 
Lehto, JT, Koskinen, PK, Anttila, VA, Lautenschlager, I, Lemström, K, Sipponen, J, Tukiainen, P, Halme, M 2005, 'Bronchoscopy in the 
diagnosis and surveillance of respiratory infections in lung and heart-lung transplant recipients', Transplant International, vol 18, no. 5, 
pp. 562-571. 
Lehto, J, Lemström, KB, Halme, M, Lappalainen, M, Lommi, J, Sipponen, J, Harjula, A, Tukiainen, PS, Koskinen, P 2005, 'A prospective 
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Vollenweider, P, Voight, BF, Vitart, V, Uitterlinden, AG, Uda, M, Tuomilehto, J, Thompson, JR, Tanaka, T, Surakka, I, Stringham, HM, 
Spector, TD, Soranzo, N, Smit, JH, Sinisalo, J, Silander, K, Sijbrands, EJG, Scuteri, A, Scott, J, Schlessinger, D, Sanna, S, Salomaa, V, 
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Montgomery, GW, Meitinger, T, McPherson, R, McCarthy, MI, McArdle, W, Masson, D, Martin, NG, Marroni, F, Mangino, M, 
Magnusson, PKE, Lucas, G, Luben, R, Loos, RJF, Lokki, M, Lettre, G, Langenberg, C, Launer, LJ, Lakatta, EG, Laaksonen, R, Kyvik, 
KO, Kronenberg, F, Koenig, IR, Khaw, K, Kaprio, J, Kaplan, LM, Johansson, A, Jarvelin, M, Janssens, ACJW, Ingelsson, E, Igi, W, 
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Haritunians, T, Hall, AS, Gyllensten, U, Guiducci, C, Groop, LC, Gonzalez, E, Gieger, C, Freimer, NB, Ferrucci, L, Erdmann, J, Elliott, P, 
Ejebe, KG, Doering, A, Dominiczak, AF, Demissie, S, Deloukas, P, de Geus, EJC, de Faire, U, Crawford, G, Collins, FS, Chen, YI, 
Caulfield, MJ, Campbell, H, Burtt, NP, Bonnycastle, LL, Boomsma, DI, Boekholdt, SM, Bergman, RN, Barroso, I, Bandinelli, S, 
Ballantyne, CM, Assimes, TL, Quertermous, T, Altshuler, D, Seielstad, M, Wong, TY, Tai, E, Feranil, AB, Kuzawa, CW, Adair, LS, 
Taylor, HA, Borecki, IB, Gabriel, SB, Wilson, JG, Holm, H, Thorsteinsdottir, U, Gudnason, V, Krauss, RM, Mohlke, KL, Ordovas, JM, 
Munroe, PB, Kooner, JS, Tall, AR, Hegele, RA, Kastelein, JJP, Schadt, EE, Rotter, JI, Boerwinkle, E, Strachan, DP, Mooser, V, 
Stefansson, K, Reilly, MP, Samani, NJ, Schunkert, H, Cupples, LA, Sandhu, MS, Ridker, PM, Rader, DJ, van Duijn, CM, Peltonen, L, 
Abecasis, GR, Boehnke, M, Kathiresan, S 2010, 'Biological, clinical and population relevance of 95 loci for blood lipids',  Nature, vol 466, 
no. 7307, pp. 707-713. 
Tyynismaa, H, Carroll, CJ, Raimundo, N, Ahola-Erkkilä, ST, Wenz, T, Ruhanen, H, Guse, K, Hemminki, A, Peltola-Mjosund, KE, Tulkki, 
V, Oresic, M, Moraes, CT, Pietilainen, K, Hovatta, I, Suomalainen, A 2010, 'Mitochondrial myopathy induces a starvation-like response', 
Human Molecular Genetics, vol 19, no. 20, pp. 3948-3958. 
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Wang, H, Liu, Y, Li, Z, Fan, X, Hemminki, A, Lieber, A 2010, 'A recombinant adenovirus type 35 fiber knob protein sensitizes lymphoma 
cells to rituximab therapy', Blood purification., vol 115, pp. 592-600. 
A2 Review in scientific journal 
2005 
Hakkarainen, T, Hemminki, AE 2005, 'Enhancement of cancer gene therapy with modified viral vectors and fusion genes',  Gene 
Therapy & Molecular Biology, vol 2005, no. 9, pp. 153-168. 
Krebs, R, Hollmen, ME, Tikkanen, JM, Wu, Y, Hicklin, DJ, Koskinen, PK, Lemstrom, KB 2005, 'Role of vascular endothelial growth 
factor (VEGF) in experimental obliterative bronchiolitis (OB)', American Journal of Transplantation , vol 5, pp. 528-529. 
Lemström, KB, Tikkanen, J, Koskinen, P, Häyry, P 2005, 'Effect of cytomegalovirus on cardiac allograft arteriosclerosis - Indirect or 
direct. Editorial.', American Journal of Transplantation, vol 5, pp. 1-2. 
Lokki, M 2005, 'HLA ja infektiot.', Duodecim, vol 121, pp. 369-375. 
Nykanen, AI, Pajusola, K, Keranen, M, Alitalo, K, Koskinen, PK, Lemstrom, KB 2005, 'Common anti-inflammatory and diverse smooth 
muscle cell effects of AAV-mediated angiopoietin-1 and-2 expression in rat cardiac allografts',  Journal of Heart and Lung 
Transplantation, vol 24, pp. S104-S104. 
2006 
Hemminki, AE, Kellokumpu-Lehtinen, P 2006, 'The impact of the EU clinical trials directive on clinical cancer research (Editorial)',  BMJ : 
British Medical Journal, no. 332, pp. 501-502. 
Hemminki, A, Kellokumpu-Lehtinen, PL 2006, 'Harmful impact of EU clinical trials directive - Academic clinical research in cancer seems 
to have no future in Europe', BMJ : British Medical Journal, vol 332, pp. 501-502. 
Nykänen, A, Tikkanen, J, Krebs, R, Keränen, MAI, Sihvola, R, Sandelin, H, Tuuminen, R, Raisky, O, Koskinen, P, Lemström, KB  2006, 
'Angiogenic growth factors in cardiac allograft rejection.', Transplantation, vol 82, no. Suppl. 1, pp. 22-24. 
Raki, M, Rein, DT, Kanerva, A, Hemminki, A 2006, 'Gene transfer approaches for gynecological diseases', Molecular therapy, vol 14, 
no. 2, pp. 154-163. 
2007 
Back, J, Kankuri, E, Ikonen, T, Pätilä, T, Sinisalo, J, Laine, M, Vapaatalo, H, Koponen, J, Hukkanen, M, Ylä-Herttuala, S, Alitalo, R, 
Kupari, M, Harjula, A 2007, 'Solusiirrot sydämen vajaatoiminnan hoidossa: [katsaus]', Duodecim, vol 123, no. 4, pp. 398-405. 
Kanerva, A, Raki, M, Hemminki, A 2007, 'Gene therapy of gynaecological diseases: [review]',  Expert Opinion on Biological Therapy, 
vol 7, no. 9, pp. 1347-1361. 
2008 
Jokinen, JJ, Kukkonen, S, Hämmäinen, P, Lommi, J, Kupari, M, Harjula, A, Sipponen, J, Lemström, KB  2008, 'Aikuisten sydämensiirrot 
Suomessa: onko määrää syytä lisätä? : katsaus', Duodecim, vol 124, pp. 1953-1961. 
Kanerva, A, Hemminki, A 2008, 'Geeniterapian mahdollisuudet munasarjasyövän hoidossa: [katsaus]', Duodecim, vol 124, no. 2, pp. 
167-174. 
2009 
Guse, K, Hemminki, A 2009, 'Cancer gene therapy with oncolytic adenoviruses', Journal of Balkan Union of Oncology , vol 14, pp. 
S7-S15. 
Toppila-Salmi, S, Renkonen, R 2009, 'Allergeeni kohtaa epiteelin.', Duodecim, vol 125, pp. 825-827. 
2010 
Ranki, T, Hemminki, A 2010, 'Serotype Chimeric Human Adenoviruses for Cancer Gene Therapy', Viruses, vol 2, pp. 2196-2212. 
Saha, H, Kyllönen , L, Salmela, K, Koskinen, P 2010, 'Kuka munuaissiirtolistalle - kriteerit 2011: katsaus', Duodecim, vol 126, no. 22, 
pp. 2591-2599. 
A3 Contribution to book/other compilations (refereed) 
2005 
Koskinen, P, Salmela, K, Honkanen, E 2005, 'Munuaisensiirtopotilaan infektiot', Akuuttihoito-opas, Duodecim, Helsinki, pp. 216-217. 
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Koskinen, P, Salmela, K, Honkanen, E 2005, 'Munuaisensiirtopotilaan akuutit ongelmat', Akuuttihoito-opas, Duodecim, Helsinki, pp. 
213-217. 
2008 
Glasgow, J, Hemminki, AE, Curiel, D 2008, 'Modified adenoviruses for gene therapy', in N Templeton (ed.), Cell and Gene Therapy . 
Therapeutic Mechanisms and Strategies., 3 edn, Marcel Dekker, New York. 
Kuusisto, J, Sinisalo, J 2008, 'Hypertrofinen kardiomyopatia', in /PJHMK;TJA.[A (ed.), Kardiologia, Duodecim, Helsinki, pp. 880-896. 
Raki, MP, Rajecki, MK, Kirn, D, Hemminki, AE 2008, 'Oncolytic viruses for treatment of cancer', in N Templeton (ed.), Cell and Gene 
Therapy . Therapeutic Mechanisms and Strategies., 3 edn, Marcel Dekker, New York. 
Sinisalo, J, Virtanen, K 2008, 'Sydämen oma verenkierto', in /PJHMK;TJA.[A (ed.), Kardiologia, Duodecim, Helsinki, pp. 292-298. 
A4 Article in conference publication (refereed) 
2008 
Keränen, MAJ, Tuuminen, R, Nykanen, AI, Tavast, E, Koskinen, PK, Johnson, RS, Lemstrom, KB  2008, Constantly stable HIF-1 alpha 
in myeloid cells prevents acute rejection in rat cardiac Allografts,, Journal of Heart and Lung Transplantation 27 ELSEVIER INC.. 
Krebs, R, Tikkanen, JM, Nykanen, AL, Alitalo, K, Ylä-Herttuala, S, Koskinen, PK, Lemström, KB 2008, Role of vascular endothelial 
growth factor-C in experimental obliterative airway disease,, Journal of Heart and Lung Transplantation 27 ELSEVIER INC.. 
2009 
Cerullo, V, Pesonen, S, Diaconu, I, Escutenaire, S, Arstila, P, Ugolini, M, Nokisalmi, P, Raki, M, Laasonen, L, Rajecki, M, Kangasniemi, 
L, Guse, K, Joensuu, T, Kanerva, A, Hemminki, A 2009, Ad5-D24-GMCSF, an oncolytic adenovirus coding for GMCSF, induces anti-
tumoral immunity in human cancer patients,, Human Gene Therapy 20 MARY ANN/LIEBERT, INC. PUBLISHERS. 
Guse, K, Tyynismaa, H, Ahola-Erkkilä, ST, Suomalainen, A, Pesonen, S, Cerullo, V, Hemminki, A 2009, Capsid Modified Adenoviruses 
Display Robust, Long Term Gene Expression in Adult Skeletal Muscle Tissue\, , Molecular therapy 17 ACADEMIC PRESS.. 
Krebs, R, Tikkanen, JM, Hollmen, M, Wu, Y, Hicklin, DJ, Koskinen, PK, Lemstrom, KB 2009, Role of Vascular Endothelial Growth 
Factor Receptors 1 and 2 in Experimental Obliterative Airway Disease, , Journal of Heart and Lung Transplantation 28 ELSEVIER INC.. 
Nykanen, AI, Sandelin, H, Krebs, R, Keranen, MAI, Tuuminen, R, Karpanen, T, Wu, Y, Pytowski, B, Koskinen, PK, Yla-Herttuala, S, 
Alitalo, K, Lemstrom, KB 2009, Targeting Lymphatic Vessel CCL21 Production by VEGFR-3 Inhibition Prevents Cardiac Allograft 
Rejection and Arteriosclerosis,, Journal of Heart and Lung Transplantation 28 ELSEVIER INC.. 
Pesonen, S, Nokisalmi, P, Escutenaire, S, Sarkioja, M, Cerullo, V, Laasonen, L, Guse, K, Haavisto, E, Oksanen, M, Rajecki, M, 
Ristimaki, A, Kantola, T, Bauerschmitz, G, Kanerva, A, Joensuu, T, Hemminki, A 2009, Efficacy, Toxicity, Correlative and Immunological 
Analysis of Cancer Patients Treated with Oncolytic Adenovirus Ad5/3-Cox2L-D24, , Molecular therapy 17 ACADEMIC PRESS.. 
Ropponen, JO, Tikkanen, JM, Hollmen, M, Krebs, R, Keranen, MA, Lemstrom, KB  2009, Simvastatin Treatment Attenuates Obliterative 
Airway Disease Development in Rat Tracheal Allograft Model,, Journal of Heart and Lung Transplantation 28 ELSEVIER INC.. 
Tuuminen, R, Nykanen, AI, Krebs, R, Lemstrom, KB 2009, Pre-Treatment of Rat Cardiac Allograft Donors with Simvastatin Prevents 
Early Ischemia-Reperfusion-Induced Vascular Permeability and Later Development of Chronic Rejection, , Journal of Heart and Lung 
Transplantation 28 ELSEVIER INC.. 
B1 Unrefereed journal article 
2005 
Lemström, K, Tikkanen, JM, Koskinen, PK, Häyry, P 2005, 'Effect of cytomegalovirus on cardiac allograft arteriosclerosis - indirect or 
direct? [editorial]', American Journal of Transplantation, vol 5, pp. 421-422. 
Lokki, M 2005, 'HLA ja infektiot', Duodecim, vol 121, pp. 369-375. 
2006 
Ryysy, R, Sinisalo, J, Viitasalo, M 2006, 'Sitalopraamimyrkytyksen aiheuttama kääntyvien kärkien kammiotakykardia: [tapausselostus]', 
Duodecim, vol 122, pp. 97-102. 
2009 
Hämmäinen, P, Kukkonen, S, Lemström, K 2009, 'Sydänluovuttajan arviointi ja hoito', Sydänääni : Suomen kardiologisen seuran 
lehti., vol 20, no. 3A, pp. 17-20. 
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Höckerstedt, K, Isoniemi, H, Mäkisalo, H, Koivusalo, A, Ilmakunnas, M, Hartikka, E, Lemström, K, Hämmäinen, P, Salmenperä, M, 
Yesil, C 2009, 'Ohjeet elintenluovuttajan hoidosta sekä elinten talteenotosta',  Tehohoito, vol 27, no. 2, pp. 122-125. 
Lemström, K, Jokinen, JJ, Lommi, J, Sipponen, J 2009, 'Sydämensiirtojen tulokset ja pullonkaulat', Sydänääni : Suomen 
kardiologisen seuran lehti., vol 20, no. 3A, pp. 11-16. 
Lemström, K, Lommi, J 2009, 'Yksilöllinen immunosuppressio on nykyaikaa', Sydänääni : Suomen kardiologisen seuran lehti., vol 
20, no. 3A, pp. 21-24. 
Toppila-Salmi, S, Renkonen, R 2009, 'Allergeeni kohtaa epiteelin: [pääkirjoitus]',  Duodecim, vol 125, no. 8, pp. 5-7. 
2010 
Pesonen, S, Helin, H, Nokisalmi, P, Escutenaire, S, Ribacka, C, Särkioja, M, Cerullo, V, Guse, K, Bauerschmitz, G, Laasonen, L, 
Kantola, T, Ristimäki, A, Rajecki, M, Oksanen, M, Haavisto, E, Kanerva, A, Joensuu, T, Hemminki, A 2010, 'Oncolytic adenovirus 
treatment of a patient with refractory neuroblastoma', Acta Oncologica, vol 49, pp. 117-119. 
B3 Unrefereed article in conference proceedings 
2008 
Ahonen, M, Diaconu, I, Baumann, M, Sarkioja, M, Pesonen, S, Hemminki, A 2008, Identification of a serum factor that can increase 
adenoviral gene transfer,, Human Gene Therapy 19 MARY ANN/LIEBERT, INC. PUBLISHERS. 
D1 Article in professional journal 
2010 
Myllykangas, LT, Paunio, T, Lundin, JE, Marjamaa, A, Silander, K, Pennanen, P, Aarnio, M, Oksanen, MK, Dias, J, Pesonen, S, 
Hemminki, AE 2010, 'Ulkomaiset lääkärit, hammaslääkärit ja tieteelliset jatko-opiskelijat Suomessa', Suomen lääkärilehti , vol 41, pp. 
3309-3314. 
E1 Popular article, newspaper article 
2010 
Ranki, T, Hemminki, AE 2010, 'Oncolytic viruses in the treatment of breast cancer', Rinnakkain. 
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